NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

kabanushi,

Think of antibody drug conjugates (ADCs) as conceptual smart bombs and DCs as the identifiers of and programmers of additional targets exposed from the cancer cells being blown up. Right now chemo/rad can only create limited access to critical targets and usually miss quite a few. The more critical targets identified and defense mechanisms destroyed the more complete the damage to the whole support structure for the tumor which at some point causes an inability to rebuild/reconstitute. Not only this but memory cells developed protect against all these same critical targets from being used again to start over if there is any escape that managed to hide again to form latent presence away from where inflammatory response was most active. This long term immune surveillance is what provides immune response protection from any future activation of latent cells.
Right now ADC targets are being selected by big pharma for antibody target specificity and relative importance based mostly on their affiliation with cancer type. The proteomics done for NWBO in patients that received L has identified known targets with exact specificity that theoretically could be used to create an ADC that is much more safe than chemo/rad and not a guess to induce the damage needed to the tumor that provides identifiable targets for the T-cells that the L vaccine educates. Imagine how much more is available from the use of Direct where the tumor environment is modified thus creating greater susceptibility to treatment and likely no need for an ADC. Big pharma is hoping for a long development period for Direct methinks; ). Best wishes.